New York, Jan 30, 2026, 21:00 EST — Market closed
- Abbott shares closed Friday around $109.30, up roughly 3% following a volatile session.
- Leerink trimmed its target and labeled Abbott a “show-me” story, while Freedom Capital raised its rating to Buy.
- CEO Robert Ford recently purchased roughly $2 million worth of Abbott shares, according to an SEC filing.
Abbott Laboratories (ABT.N) shares ended Friday roughly 3% higher, closing at $109.30. The stock had dipped to a session low around $105.72 earlier, with volume picking up noticeably as traders wrapped up the week.
The bounce is significant, given the stock’s struggle to regain ground following a sharp selloff fueled by doubts over 2026 growth, particularly in nutrition and diagnostics. Markets are closed for now, but all eyes turn to Monday when U.S. trading kicks back in.
The near-term story is straightforward: investors are looking for evidence. Abbott’s 2026 plan counts on progress later in the year, and the market is beginning to factor in a broader set of possibilities.
Leerink Partners cut its price target for Abbott from $136 to $119 on Friday, maintaining a Market Perform rating. The firm described Abbott as a “show-me” story that might take several quarters to regain investor confidence. It cited softer-than-expected trends in Nutrition and other segments but highlighted upcoming 2026 launches like Abbott’s Volt pulsed field ablation system — a heart-rhythm treatment using electrical pulses — and a dual analyte sensor. Investing.com
Freedom Capital Markets raised Abbott to Buy from Hold just a day ago, but cut the price target to $120 from $130. The firm said the recent pullback had reset expectations, and called Abbott’s organic growth forecast conservative. It noted management anticipates Nutrition segment weakness will persist through the first half of the year, while also pointing to the planned integration of Exact Sciences in Q2.
On Jan. 22, Abbott projected adjusted diluted earnings for 2026 between $5.55 and $5.80 per share, alongside organic sales growth of 6.5% to 7.5%. The company defines “organic” as excluding currency fluctuations and certain one-time items. CEO Robert B. Ford described Abbott as “well positioned for accelerating growth in 2026.” The firm also reaffirmed its plan to complete the Exact Sciences deal in Q2, highlighting recent regulatory approvals in its heart-rhythm business. Abbott MediaRoom
Insider moves caught attention too. On Jan. 23, a Form 4 filing revealed Ford purchased 18,800 Abbott shares at an average price of $107.1259 via the Ford Family Trust.
Investors have a narrow focus right now: they’re watching for the nutrition segment to steady, hoping for fewer hiccups in diagnostics, and looking for consistent demand in devices. Abbott’s diabetes sensors take on Dexcom, while its electrophysiology and heart-device products face competition from Medtronic and Boston Scientific.
There is, however, a clear downside risk. Should nutrition pricing and volumes fail to pick up as management expects, or if the Exact Sciences integration proves more complicated, the stock could lose any “valuation floor” support that emerges following steep selloffs.
Next week features a series of medical-device events, notably the Society of Thoracic Surgeons conference in New Orleans, running through Feb. 2. This event frequently unveils new data and product buzz that can shake up individual stocks.
